Breaking News

Financial Report: Charles River Labs

May 1, 2014

Preclinical segment sales up 5% in the quarter

Charles River Labs
 
1Q Revenues: $299.4 million (+3%)

1Q Earnings: $32.4 million (+26%)

Comments: RMS segment sales were $185.6 million in the quarter, up 2%, with growth in the Endotoxin and Microbial Detection (EMD) business. Preclinical Services (PCS) segment sales were $113.8 million, up 5% driven by continued demand from mid-tier biotechnology clients.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks